Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company's product pipeline includes norovirus vaccine, an oral tabl
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.